正文
获取原文件REPORT_TEMPLATE.md
All 14 sections below MUST be present in every feasibility report.
File naming: [INDICATION]_trial_feasibility_report.md
1. Executive Summary
# Clinical Trial Feasibility Report: [INDICATION]
**Date**: [YYYY-MM-DD]
**Trial Type**: [Phase 1/2, biomarker-selected, basket, etc.]
**Primary Endpoint**: [ORR, PFS, DLT, etc.]
**Feasibility Score**: [0-100] - [LOW/MODERATE/HIGH]
## Key Findings
- **Patient Availability**: [Est. enrollable patients/year in US]
- **Enrollment Timeline**: [Months to target N]
- **Endpoint Precedent**: [Grade A/B/C/D] - [Description]
- **Regulatory Pathway**: [505(b)(1), breakthrough, orphan, etc.]
- **Critical Risks**: [Top 3 feasibility risks]
## Go/No-Go Recommendation
[RECOMMEND PROCEED / RECOMMEND ADDITIONAL VALIDATION / DO NOT RECOMMEND]
Rationale: [2-3 sentence summary]
2. Disease Background
- Indication definition
- Prevalence and incidence (with sources)
- Current standard of care
- Unmet medical need
- Disease biology relevant to trial design
3. Patient Population Analysis
## 3.1 Base Population Size
- **US Incidence**: [X per 100,000] [evidence grade: Source]
- **Prevalence**: [Y total patients in US] [evidence grade: CDC/NCI data]
- **Annual new cases**: [Z patients/year]
## 3.2 Biomarker Selection Impact
- **Biomarker**: [e.g., EGFR L858R mutation]
- **Prevalence in disease**: [%] [evidence grade: ClinVar/COSMIC]
- **Geographic variation**: [Asian vs. Caucasian, etc.]
- **Testing availability**: [FDA-approved tests, CLIA labs]
## 3.3 Eligibility Criteria Funnel
| Criterion | Remaining Patients | % Retained |
|-----------|-------------------|------------|
| Base disease population | [N] | 100% |
| Biomarker positive | [N x biomarker %] | [%] |
| Age 18-75 | [N x age factor] | [%] |
| No prior therapy | [N x treatment-naive %] | [%] |
| ECOG 0-1 | [N x performance factor] | [%] |
| Adequate organ function | [N x eligibility factor] | [%] |
| **FINAL ELIGIBLE POOL** | **[N]** | **[%]** |
## 3.4 Geographic Distribution
- High-incidence regions: [e.g., Asia 50%, US 15% for EGFR+]
- Trial site implications
- Recruitment strategy recommendations
## 3.5 Enrollment Projections
**Assumptions**:
- Eligible pool: [N patients/year in US]
- Site activation: [M sites]
- Screening success rate: [%]
- Patients per site per month: [X]
**Target Enrollment**: [Total N]
**Projected Timeline**: [Months]
**Sites Required**: [Minimum M sites]
4. Biomarker Strategy
## 4.1 Primary Biomarker
- **Biomarker**: [Gene mutation, protein expression, etc.]
- **Prevalence**: [%] [evidence grade: ClinVar data]
- **Assay Type**: [NGS, IHC, PCR, etc.]
- **FDA-Approved Tests**: [List CDx tests]
- **Turnaround Time**: [Days]
- **Cost**: [$X per test]
## 4.2 Alternative/Complementary Biomarkers
| Biomarker | Prevalence | Correlation | Testing |
|-----------|------------|-------------|---------|
| [Alt 1] | [%] | [R-squared] | [Method] |
| [Alt 2] | [%] | [R-squared] | [Method] |
## 4.3 Biomarker Testing Logistics
- Pre-screening vs. screening approach
- Central lab vs. local testing
- Tissue vs. liquid biopsy (ctDNA)
- Quality control requirements
5. Endpoint Selection & Justification
## 5.1 Primary Endpoint
**Proposed**: [e.g., Objective Response Rate (ORR)]
**Regulatory Precedent** [evidence grade]:
- [N] FDA approvals in [indication] using ORR (2015-2024)
- Recent example: [Drug] approved [Year] (ORR XX%, n=YY)
- Source: search_clinical_trials, FDA_get_approval_history
**Measurement Feasibility**:
- Assessment method: [RECIST 1.1, irRECIST, etc.]
- Imaging modality: [CT, MRI, PET]
- Assessment frequency: [Every X weeks]
- Independent review: [Yes/No, cost]
**Statistical Considerations**:
- Expected ORR: [%] (based on [source])
- Null hypothesis: [%]
- Sample size: [N] (alpha=0.05, beta=0.20, two-sided)
- Response duration: [Median months]
## 5.2 Secondary Endpoints
| Endpoint | Evidence Grade | Feasibility | Rationale |
|----------|----------------|-------------|-----------|
| Progression-Free Survival (PFS) | A | High | FDA-accepted, precedent in [trials] |
| Duration of Response (DoR) | B | High | Standard in oncology |
| Overall Survival (OS) | A | Low (early phase) | Follow-up for long-term |
| [Biomarker response] | C | Medium | Exploratory, mechanistic |
## 5.3 Exploratory Endpoints
- Pharmacodynamic biomarkers (proof-of-mechanism)
- ctDNA clearance (liquid biopsy)
- Quality of life (PRO-CTCAE)
- Correlative science (tumor profiling)
## 5.4 Endpoint Risks & Mitigation
- Risk: [Low response rate -> sample size inflation]
- Mitigation: [Adaptive design, interim analysis]
6. Comparator Analysis
## 6.1 Standard of Care
**Current SOC**: [Drug name(s)]
- FDA approval: [Year] [evidence grade: FDA_OrangeBook]
- Efficacy: [ORR/PFS from pivotal trial]
- Limitations: [Resistance, toxicity, access]
**SOC Comparator Feasibility**: [HIGH/MEDIUM/LOW]
## 6.2 Trial Design Options
### Option A: Single-Arm vs. SOC
- **Design**: Phase 2, single-arm, N=[X]
- **Comparator**: Historical SOC data (ORR=[%])
- **Pros**: Faster enrollment, smaller N
- **Cons**: Selection bias, regulatory skepticism
- **Feasibility Score**: [0-100]
### Option B: Randomized vs. SOC
- **Design**: Phase 2, 1:1 randomization, N=[X] per arm
- **Comparator**: Active control ([SOC drug])
- **Pros**: Robust comparison, regulatory preferred
- **Cons**: 2x enrollment, comparator sourcing
- **Feasibility Score**: [0-100]
### Option C: Non-Inferiority Design
- **Rationale**: [If aiming for better safety with similar efficacy]
- **Non-inferiority margin**: [delta = X%]
- **Sample size**: [N] (larger than superiority)
## 6.3 Comparator Drug Sourcing
- Commercial availability: [Yes/No]
- Patent status: [Generic available?]
- Cost: [$X per course]
- Stability and storage: [Requirements]
7. Safety Endpoints & Monitoring Plan
## 7.1 Primary Safety Endpoint
**Dose-Limiting Toxicity (DLT)** [for Phase 1 component]:
- DLT definition: [Grade 3+ non-hematologic, Grade 4+ hematologic]
- DLT assessment period: [Cycle 1, 28 days]
- Dose escalation rule: [3+3, BOIN, mTPI]
## 7.2 Mechanism-Based Toxicities
**Drug Class**: [Kinase inhibitor, checkpoint inhibitor, etc.]
**Expected Toxicities** [evidence grade: FAERS, label data]:
| Toxicity | Incidence | Grade 3+ | Monitoring |
|----------|-----------|----------|------------|
| Diarrhea | 60% | 10% | Symptom diary, hydration |
| Rash | 40% | 5% | Dermatology consult PRN |
| Hepatotoxicity | 20% | 3% | LFTs weekly (cycle 1), then q3w |
| [Specific AE] | [%] | [%] | [Plan] |
**Data Source**: FAERS_search_reports (similar drugs), drugbank_get_pharmacology
## 7.3 Organ-Specific Monitoring
### Hepatic
- Baseline: LFTs, hepatitis panel
- Monitoring: AST/ALT/bili weekly (cycle 1), then q3w
- Stopping rule: ALT >5x ULN or bili >3x ULN
### Cardiac
- Baseline: ECG, ECHO if anthracycline history
- Monitoring: ECG q cycle, ECHO if symptoms
- Stopping rule: QTcF >500 ms, LVEF drop >15%
### Renal
- Baseline: Cr, eGFR, urinalysis
- Monitoring: Cr/eGFR q cycle
- Stopping rule: CrCl <30 mL/min
## 7.4 Safety Monitoring Committee (SMC)
- Composition: [3 independent experts: oncologist, toxicologist, biostatistician]
- Review frequency: [After every 6 patients, then quarterly]
- Stopping rules: [>=3 DLTs at dose level, >=2 drug-related deaths]
8. Study Design Recommendations
## 8.1 Recommended Design
**Phase**: [1/2, 1b/2, 2]
**Design Type**: [Single-arm, randomized, basket, umbrella]
**Primary Objective**: [Assess safety and preliminary efficacy]
**Schema**:
[Indication + Biomarker]
-> Screening (Biomarker testing)
-> Enrollment
|-- [Phase 1 dose escalation: 3+3 design, N=12-18]
| Dose Levels: [X mg, Y mg, Z mg QD]
| DLT assessment: Cycle 1 (28 days)
+-- [Phase 2 expansion: Simon 2-stage, N=43]
Stage 1: N=13 (>=2 responses to proceed)
Stage 2: N=30 additional
Target ORR: 30% (H0: 10%, alpha=0.05, beta=0.20)
## 8.2 Eligibility Criteria
**Inclusion**:
- Age >=18 years
- Histologically confirmed [disease]
- [Biomarker] positive (central lab confirmed)
- Measurable disease per RECIST 1.1
- ECOG PS 0-1
- Adequate organ function
- [<=1 prior line for advanced disease]
**Exclusion**:
- Brain metastases (unless treated and stable)
- Prior [drug class] therapy
- Active infection, immunodeficiency
- Pregnancy/nursing
- Significant cardiovascular disease
## 8.3 Treatment Plan
- **Dosing**: [X mg PO QD, 28-day cycles]
- **Dose modifications**: [20% reductions for Grade 2+]
- **Duration**: Until progression, toxicity, or 24 months
- **Concomitant meds**: Supportive care allowed, restrictions on CYP3A4 inhibitors
## 8.4 Assessment Schedule
| Assessment | Screening | Cycle 1 | Cycles 2-6 | Cycles 7+ | EOT |
|------------|-----------|---------|------------|-----------|-----|
| History & PE | X | X | X | X | X |
| ECOG PS | X | X | X | X | X |
| Labs (CBC, CMP, LFT) | X | Weekly | q3w | q3w | X |
| Tumor imaging | X | - | q6w | q9w | X |
| ECG | X | - | q3w (if abnormal) | - | X |
| Biomarker (ctDNA) | X | C1D15 | q6w | - | X |
| AE assessment | - | Continuous | Continuous | Continuous | X |
9. Enrollment & Site Strategy
## 9.1 Site Selection Criteria
**Required Capabilities**:
- [Biomarker] testing (or central lab partnership)
- Phase 1/2 experience
- GCP compliance, IRB approval
- Access to [patient population]
- Investigator publications in [indication]
**Geographic Distribution**:
- US sites: [N] (target regions: [high-incidence areas])
- International: [Consider Asia if biomarker enriched there]
## 9.2 Enrollment Projections
**Assumptions**:
- Screening rate: [X patients/site/month]
- Screen failure rate: [30%] (biomarker negative, eligibility)
- Enrollment rate: [Y patients/site/month]
**Timeline** (N=[total]):
| Milestone | Month | Cumulative Enrolled |
|-----------|-------|---------------------|
| First site activated | 0 | 0 |
| First patient enrolled | 1 | 1 |
| 25% enrollment | [M1] | [0.25N] |
| 50% enrollment | [M2] | [0.5N] |
| 75% enrollment | [M3] | [0.75N] |
| Last patient enrolled | [M4] | [N] |
| Primary analysis | [M4 + follow-up] | - |
**Sites Required**: [Minimum M sites to achieve timeline]
## 9.3 Recruitment Strategies
- Physician outreach: Academic consortia, tumor boards
- Patient advocacy groups: [Organization names]
- ClinicalTrials.gov listing (prominent, lay summary)
- Social media: Targeted ads in [indication] communities
- Referral network: Community oncologists
10. Regulatory Pathway
## 10.1 FDA Pathway Selection
**Recommended**: [505(b)(1) / 505(b)(2) / Breakthrough / Orphan]
**Rationale**:
- [505(b)(1)]: New molecular entity, full development program
- [505(b)(2)]: [If relying on published safety data for similar drugs]
- **Breakthrough Therapy**: [If preliminary evidence of substantial improvement]
- Criteria: [X-fold ORR vs. SOC in early data]
- Benefits: Rolling review, frequent FDA meetings
- **Orphan Designation**: [If prevalence <200,000 in US]
- Benefits: 7-year exclusivity, tax credits, fee waivers
## 10.2 Regulatory Precedents
**Similar Approvals** [evidence grade]:
- [Drug A]: [Indication], [Year], [Endpoint used], [N=X], [ORR=Y%]
- [Drug B]: [Indication], [Year], [Accelerated approval -> full]
- Source: FDA_get_approval_history, drug labels
**FDA Guidance Documents**:
- [Relevant guidance title] (Year)
- Key recommendations: [e.g., ORR acceptable for Phase 2, confirmatory trial needed]
## 10.3 Pre-IND Meeting
**Recommended Topics**:
1. Primary endpoint acceptability (ORR vs. PFS)
2. Biomarker test qualification (CDx plan)
3. Comparator arm (single-arm acceptable?)
4. Pediatric study plan waiver
5. Safety monitoring plan
**Timing**: [3-4 months before IND submission]
## 10.4 IND Timeline
| Milestone | Month | Deliverable |
|-----------|-------|-------------|
| Pre-IND meeting request | -4 | Briefing package |
| Pre-IND meeting | -3 | FDA feedback |
| IND submission | 0 | Complete IND package |
| FDA 30-day review | 1 | Clinical hold or proceed |
| First patient dosed | 1-2 | After IND clearance |
11. Budget & Resource Considerations
## 11.1 Cost Drivers
| Item | Cost Estimate | Notes |
|------|---------------|-------|
| Protocol development | $50-100K | CRO or internal |
| IND preparation | $100-200K | CMC, toxicology reports |
| Site activation | $50K/site x [M sites] | IRB, contracts |
| Patient recruitment | $200-500K | Advertising, patient navigation |
| [Biomarker] testing | $[X]/patient | Central lab, CDx |
| Imaging (RECIST) | $3-5K/scan x [N scans] | CT, independent review |
| Drug supply | [Depends on sponsor] | If not sponsor-provided |
| CRO monitoring | $100-300/hour | Site visits, SDV |
| Data management | $150-300K | EDC, database lock |
| Statistical analysis | $50-100K | SAP, CSR |
| **TOTAL (Phase 1/2)** | **$[X-Y]M** | [N patients, M sites] |
## 11.2 Timeline & FTE Requirements
**Duration**: [X months] (enrollment) + [Y months] (follow-up)
**Team**:
- Medical monitor: 0.5 FTE
- Project manager: 0.8 FTE
- Clinical operations: 0.3 FTE
- Data manager: 0.3 FTE
- Biostatistician: 0.2 FTE
12. Risk Assessment
## 12.1 Feasibility Risks (High Priority)
| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Slow enrollment (biomarker screen fail) | HIGH | HIGH | Expand sites, allow alternative biomarkers, liquid biopsy screening |
| Low response rate (ORR <10%) | MEDIUM | CRITICAL | Interim futility analysis, lower null hypothesis, pivot to combination |
| Unexpected toxicity (>33% DLT rate) | LOW | CRITICAL | Conservative starting dose, adaptive escalation (BOIN), close SMC oversight |
| Comparator drug supply issues | MEDIUM | MEDIUM | Secure commercial supply early, generic sourcing |
| Regulatory pushback on single-arm design | MEDIUM | HIGH | Pre-IND meeting, plan for randomized Phase 2b if needed |
## 12.2 Scientific Risks
- Biomarker hypothesis unvalidated: [Correlative studies to de-risk]
- Patient heterogeneity: [Stratification by [factor]]
- Resistance mechanisms: [Serial biopsies for molecular profiling]
13. Success Criteria & Go/No-Go Decision
## 13.1 Phase 1 Success Criteria (Go to Phase 2)
- [ ] <=33% DLT rate at RP2D
- [ ] >=50% patients achieve [PD biomarker response]
- [ ] No unexpected safety signals (Grade 5 AEs, new class effects)
- [ ] PK supports QD dosing
## 13.2 Phase 2 Interim Analysis (Simon Stage 1)
- **Enrollment**: 13 patients
- **Decision Rule**:
- >=2 responses (ORR >=15%) -> Proceed to Stage 2
- <2 responses -> Stop for futility
## 13.3 Phase 2 Final Success Criteria (Advance to Phase 3)
- [ ] ORR >=30% (95% CI lower bound >10%)
- [ ] Median DoR >=6 months
- [ ] PFS signal (HR <0.7 vs. historical SOC)
- [ ] Safety profile manageable (Grade >=3 AE <40%)
- [ ] Biomarker correlation with response (enrichment signal)
## 13.4 Feasibility Scorecard
| Dimension | Weight | Score (0-10) | Weighted | Grade |
|-----------|--------|--------------|----------|-------|
| **Patient Availability** | 30% | [X] | [0.30xX] | [grade] |
| - Base population size | - | [X] | - | [Source] |
| - Biomarker prevalence | - | [X] | - | [ClinVar data] |
| - Site access | - | [X] | - | [N sites feasible] |
| **Endpoint Precedent** | 25% | [X] | [0.25xX] | [grade] |
| - Regulatory acceptance | - | [X] | - | [FDA approvals using ORR] |
| - Measurement feasibility | - | [X] | - | [RECIST standard] |
| **Regulatory Clarity** | 20% | [X] | [0.20xX] | [grade] |
| - Pathway defined | - | [X] | - | [Breakthrough potential] |
| - Precedent approvals | - | [X] | - | [Similar indications] |
| **Comparator Feasibility** | 15% | [X] | [0.15xX] | [grade] |
| - SOC availability | - | [X] | - | [FDA-approved, generic] |
| - Historical data | - | [X] | - | [Published ORR: X%] |
| **Safety Monitoring** | 10% | [X] | [0.10xX] | [grade] |
| - Known toxicities | - | [X] | - | [FAERS, class effects] |
| - Monitoring plan | - | [X] | - | [Defined, feasible] |
| **TOTAL FEASIBILITY SCORE** | **100%** | - | **[XX/100]** | - |
**Interpretation**:
- **>=75**: HIGH feasibility - Recommend proceed to protocol development
- **50-74**: MODERATE feasibility - Additional validation recommended
- **<50**: LOW feasibility - Significant de-risking required
14. Recommendations & Next Steps
## 14.1 Final Recommendation
**GO / CONDITIONAL GO / NO-GO**: [Decision]
**Rationale**: [2-3 paragraphs synthesizing feasibility analysis]
## 14.2 Critical Path to IND
**Immediate Next Steps** (Months 0-3):
- [ ] Request pre-IND meeting with FDA
- [ ] Initiate CDx partnership for [biomarker] test
- [ ] Secure drug supply (GMP manufacturing, stability)
- [ ] Draft protocol (v1.0) and ICF
- [ ] Site feasibility surveys (target [M] sites)
**IND Preparation** (Months 3-6):
- [ ] Complete CMC section
- [ ] Finalize preclinical package
- [ ] Prepare clinical protocol (incorporate FDA feedback)
- [ ] Develop CRFs and EDC database
- [ ] IND submission (Month 6)
**Post-IND** (Months 6-9):
- [ ] IRB submissions (central IRB for multi-site)
- [ ] Site contracts and budgets
- [ ] Investigator meeting
- [ ] First patient enrolled (Month 7-8)
## 14.3 Alternative Designs (If Current Design Infeasible)
**Plan B**: Broaden biomarker criteria, add international sites, basket design
**Plan C**: Randomized Phase 2 (if single-arm rejected by FDA)
## 14.4 Long-Term Development Strategy
- Phase 3 design, companion diagnostic, commercial readiness, patent strategy
- Market considerations: addressable market, competitive landscape, differentiation, pricing